VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

WCLC Sept 2021 | Results from Phase I/II study of DS-7300a in advanced solid tumors

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, gives an update on the results of a Phase I/II dose-escalation study evaluating DS-7300a, a novel antibody-drug conjugate (ADC) directed against B7H3 in patients with advanced solid malignant tumors (NCT04145622). The trial reported activity and tolerability at different dose levels in castrate-resistant prostate cancer (CRPC), squamous cell carcinomas (SCC) of the head and neck, of the lung and of the gastro-esophageal junction. It is known that B7H3 is also expressed across a wide range of tumor types where it is associated with a poor prognosis and poor treatment response to anti-PD-1 therapy. Preliminary results suggest that DS-7300a may be a promising treatment strategy post-chemotherapy and post-immunotherapy in many tumor types. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.


Research funding (all payments made to institution): AbbVie,  Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Boehringer Ingelheim, Calithera Biosciences, Checkpoint Therapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, Erasca, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Loxo Oncology, Lycera, Memorial , Sloan-Kettering, Merck, Mirati Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, OncoMed Pharmaceuticals, Pfizer, PMV Pharmaceuticals, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals / Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY, Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, WindMIL, Y-mAbs Therapeutics
Consulting/advisory role (all payments made to institution): AbbVie, Achilles Therapeutics, Amgen, AstraZeneca, Axelia Oncology, Atreca, Black Diamond, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, EMD Serono, G1 Therapeutics, Genentech / Roche, Genmab, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Ideaya Biosciences, iTeos, Incyte, Janssen, Lilly, Loxo Oncology, Merck, Mirati Therapeutics, Novartis, Oncorus, Pfizer, Regeneron Pharmaceuticals, Ribon Therapeutics, Sanofi-Aventis, Turning , Point Therapeutics, WindMIL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter